Last updated October 21, 2026. Approval line checked October 21, 2026. Compounding sources checked October 10, 2026.
FDA status
Not approved
Not approved. This record is not an FDA-approved drug product. Approval, where it exists, is specific to a drug product, indication, and route.
FDA primary source on fileBy signing up you agree to get PeptideX update emails. Unsubscribe anytime. Educational only, not medical advice.
Evidence tier
Animal Only. The tier is the highest indexed study type. It is not a safety rating and it is not an FDA approval. Confidence score 2/5. 3,200 PubMed citations indexed.
Human host defense peptide disrupting bacterial membranes and modulating innate immune responses; stimulates angiogenesis and wound healing via FPRL1 receptor activation.
What the literature studies
Antimicrobial & Immune Defense
Evidence tier
Animal Only
Compounding record
Nomination withdrawn
Nomination withdrawn. FDA substance context: Cathelicidin LL-37. Previously in Category 2; FDA still identifies potential significant safety risks. Withdrawal is not FDA approval or a determination of safety or compounding eligibility. Research information is not evidence of FDA approval. Approval, where applicable, is specific to a drug product, indication and route.
Regulatory source checked October 10, 2026. This compounding label is separate from the approval line above.
immunogenicity concerns; research findings suggest detrimental effects on male reproduction and protumorigenic potential.
By signing up you agree to get PeptideX update emails. Unsubscribe anytime. Educational only, not medical advice.
Educational only. Not medical advice. This page does not give doses or sourcing. See the medical and editorial disclaimer.